Investors Shouldn't Be Too Comfortable With Laurus Labs' (NSE:LAURUSLABS) Earnings

Unsurprisingly, Laurus Labs Limited's (NSE:LAURUSLABS) stock price was strong on the back of its healthy earnings report. However, our analysis suggests that shareholders may be missing some factors that indicate the earnings result was not as good as it looked.

earnings-and-revenue-history
NSEI:LAURUSLABS Earnings and Revenue History June 11th 2025
Advertisement

How Do Unusual Items Influence Profit?

For anyone who wants to understand Laurus Labs' profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit gained from ₹571m worth of unusual items. We can't deny that higher profits generally leave us optimistic, but we'd prefer it if the profit were to be sustainable. We ran the numbers on most publicly listed companies worldwide, and it's very common for unusual items to be once-off in nature. And that's as you'd expect, given these boosts are described as 'unusual'. If Laurus Labs doesn't see that contribution repeat, then all else being equal we'd expect its profit to drop over the current year.

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

Portfolio Valuation calculation on simply wall st

Our Take On Laurus Labs' Profit Performance

We'd posit that Laurus Labs' statutory earnings aren't a clean read on ongoing productivity, due to the large unusual item. Therefore, it seems possible to us that Laurus Labs' true underlying earnings power is actually less than its statutory profit. But the happy news is that, while acknowledging we have to look beyond the statutory numbers, those numbers are still improving, with EPS growing at a very high rate over the last year. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. With this in mind, we wouldn't consider investing in a stock unless we had a thorough understanding of the risks. While conducting our analysis, we found that Laurus Labs has 1 warning sign and it would be unwise to ignore it.

Today we've zoomed in on a single data point to better understand the nature of Laurus Labs' profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About NSEI:LAURUSLABS

Laurus Labs

Manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally.

Reasonable growth potential with proven track record.

Advertisement

Weekly Picks

DA
davidlsander
UBI logo
davidlsander on Ubisoft Entertainment ·

Is Ubisoft the Market’s Biggest Pricing Error? Why Forensic Value Points to €33 Per Share

Fair Value:€33.887.7% undervalued
33 users have followed this narrative
3 users have commented on this narrative
19 users have liked this narrative
TO
Tokyo
MC logo
Tokyo on LVMH Moët Hennessy - Louis Vuitton Société Européenne ·

EU#4 - Turning Heritage into the World’s Strongest Luxury Empire

Fair Value:€750.0428.5% undervalued
4 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
WE
WealthAP
GOOGL logo
WealthAP on Alphabet ·

The "Easy Money" Is Gone: Why Alphabet Is Now a "Show Me" Story

Fair Value:US$386.4313.8% undervalued
62 users have followed this narrative
1 users have commented on this narrative
19 users have liked this narrative

Updated Narratives

AN
andre_santos
NOVO B logo
andre_santos on Novo Nordisk ·

Novo Nordisk - A Fundamental and Historical Valuation

Fair Value:DKK 322.435.5% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
DA
davidlsander
UBI logo
davidlsander on Ubisoft Entertainment ·

Is Ubisoft the Market’s Biggest Pricing Error? Why Forensic Value Points to €33 Per Share

Fair Value:€33.887.7% undervalued
33 users have followed this narrative
3 users have commented on this narrative
0 users have liked this narrative
TA
Talos
AMD logo
Talos on Advanced Micro Devices ·

The "David vs. Goliath" AI Trade – Why Second Place is Worth Billions

Fair Value:US$441.5854.7% undervalued
21 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

WE
WealthAP
PYPL logo
WealthAP on PayPal Holdings ·

The "Sleeping Giant" Stumbles, Then Wakes Up

Fair Value:US$8250.0% undervalued
86 users have followed this narrative
6 users have commented on this narrative
35 users have liked this narrative
OO
NEO logo
OOO97 on Neo Performance Materials ·

Undervalued Key Player in Magnets/Rare Earth

Fair Value:CA$25.3321.7% undervalued
75 users have followed this narrative
0 users have commented on this narrative
19 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$253.0231.2% undervalued
1051 users have followed this narrative
6 users have commented on this narrative
32 users have liked this narrative
Advertisement